Pharmacological prevention and treatment of acute pancreatitis: Where are we now?

Digestive Diseases

Volumn 24, Issue 1-2, 2006, Pages 148-159

  Lankisch, Paul Georg ^a   Lerch, Markus M ^b  

^a Municipal Hospital of Lueneburg   (Germany)

^b UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

Acute pancreatitis; Pharmacological prevention; Pharmacological treatment; Post endoscopic retrograde cholangiopancreatography pancreatitis

Indexed keywords

ACETYLCYSTEINE; ALLOPURINOL; ANTIBIOTIC AGENT; APROTININ; BETA CAROTENE; BUPRENORPHINE; CALCIUM CHANNEL BLOCKING AGENT; CARBAPENEM DERIVATIVE; CONTRAST MEDIUM; CORTICOSTEROID; DICLOFENAC; FENTANYL; GABEXATE MESILATE; GLYCERYL TRINITRATE; HEPARIN DERIVATIVE; INDOMETACIN; INTERLEUKIN 10; LIDOCAINE; NONIONIC CONTRAST MEDIUM; NONSTEROID ANTIINFLAMMATORY AGENT; OCTREOTIDE; OPIATE DERIVATIVE; PANCREAS ENZYME; PROCAINE; PROTEINASE; PROTEINASE INHIBITOR; SELENIUM; SOMATOSTATIN; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; UNINDEXED DRUG;

ACUTE PANCREATITIS; ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG EFFECT; DRUG EFFICACY; DRUG TREATMENT FAILURE; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; ENZYME ACTIVITY; ENZYME INHIBITION; EPIDURAL ANESTHESIA; HUMAN; HYPERAMYLASEMIA; MORTALITY; PANCREAS NECROSIS; PANCREAS SECRETION; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

ANALGESICS; ANTI-INFLAMMATORY AGENTS; ANTIFIBRINOLYTIC AGENTS; ANTIOXIDANTS; HUMANS; PANCREATITIS, ACUTE NECROTIZING; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 33646741762     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000090318     Document Type: Review

References (158)

1. Talamini G, Bassi C, Falconi M, Sartori N, Frulloni L, Di Francesco V, Vesentini S, Pederzoli P, Cavallini G: Risk of death from acute pancreatitis. Int J Pancreatol 1996;19:15-24.
2. Lowham A, Lavelle J, Leese T: Mortality from acute pancreatitis. Late septic deaths can be avoided but some early deaths still occur. Int J Pancreatol 1999;25:103-106.
3. McKay CJ, Evans S, Sinclair M, Carter CR, Imrie CW: High early mortality rate from acute pancreatitis in Scotland, 1984-1995. Br J Surg 1999;86:1302-1305.
4. Mutinga M, Rosenbluth A, Tenner SM, Odze RR, Sica GT, Banks PA: Does mortality occur early or late in acute pancreatitis? Int J Pancreatol 2000;28:91-95.
5. Blum T, Maisonneuve P, Lowenfels AB, Lankisch PG: Fatal outcome in acute pancreatitis: Its occurrence and early prediction. Pancreatology 2001;1:237-241.
6. Grönroos JM, Nylamo EI: Mortality in acute pancreatitis in Turku university central hospital 1971-1995. Hepatogastroenterology 1999;46:2572-2574.
7. Goldacre MJ, Roberts SE: Hospital admission for acute pancreatitis in an English population, 1963-98: database study of incidence and mortality. Br Med J 2004;328:1466-1469.
8. Lowenfels AB, Lankisch PG, Maisonneuve P: What is the risk of biliary pancreatitis in patients with gallstones? Gastroenterology 2000;119:879-880.
9. Lankisch PG, Lowenfels AB, Maisonneuve P: What is the risk of alcoholic pancreatitis in heavy drinkers? Pancreas 2002;25:411-412.
10. Sherman S, Lehman GA: ERCP- and endoscopic sphincterotomy-induced pancreatitis. Pancreas 1991;6:350-367.
11. Fung ASY, Tsiotos GG, Sarr MG: ERCP-induced acute necrotizing pancreatitis: is it a more severe disease? Pancreas 1997;15:217-221.
12. Messmann H, Vogt W, Holstege A, Lock G, Heinisch A, von Fürstenberg A, Leser HG, Zirngibl H, Schölmerich J: Post-ERP pancreatitis as a model for cytokine induced acute phase response in acute pancreatitis. Gut 1997;40:80-85.
13. Freeman ML, Guda NM: Prevention of post-ERCP pancreatitis: a comprehensive review. Gastrointest Endosc 2004;59:845-864.
14. Pande H, Thuluvath PJ: Pharmacological prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis. Drugs 2003;63:1799-1812.
15. Sand J, Nordback I: Prospective randomized trial of the effect of nifedipine on pancreatic irritation after endoscopic retrograde cholangiopancreatography. Digestion 1993;54:105-111.
16. Prat F, Amaris J, Ducot B, Bocquentin M, Fritsch J, Choury AD, Pelletier G, Buffet C: Nifedipine for prevention of post-ERCP pancreatitis: a prospective, double-blind randomized study. Gastrointest Endosc 2002;56:202-208.
17. Schwartz JJ, Lew RJ, Ahmad NA, Shah JN, Ginsberg GG, Kochman ML, Brensinger CM, Long WB: The effect of lidocaine sprayed on the major duodenal papilla on the frequency of post-ERCP pancreatitis. Gastrointest Endosc 2004;59:179-184.
18. Hannigan BF, Keeling PWN, Slavin B, Thompson RPH: Hyperamylasemia after ERCP with ionic and non-ionic contrast media. Gastrointest Endosc 1985;31:109-110.
19. Cunliffe WJ, Cobden I, Lavella MI, Lendrum R, Tait NP, Venables CW: A randomised, prospective study comparing two contrast media in ERCP. Endoscopy 1987;19:201-202.
20. O'Connor HJ, Ellis WR, Manning AP, Lintott DJ, McMahon MJ, Axon ATR: Iopamidol as contrast medium in endoscopic retrograde pancreatography: a prospective randomised comparison with diatrizoate. Endoscopy 1988;20:244-247.
21. Sherman S, Hawes RH, Rathgaber SW, Uzer MF, Smith MT, Khusro QE, Silverman WB, Earle DT, Lehman GA: Post-ERCP pancreatitis: Randomized, prospective study comparing a low- and high-osmolality contrast agent. Gastrointest Endosc 1994;40:422-427.
22. Johnson GK, Geenen JE, Bedford RA, Johanson J, Cass O, Sherman S, Hogan WJ, Ryan M, Silverman W, Edmundowicz S, Payne M, and other members of Midwest Pancreaticobiliary Study Group: A comparison of nonionic versus ionic contrast media: results of a prospective multicenter study. Gastrointest Endosc 1995;42:312-316.
23. George S, Kulkarni AA, Stevens G, Forsmark CE, Draganov P: Role of osmolality of contrast media in the development of post-ERCP pancreatitis: a meta-analysis. Dig Dis Sci 2004;49:503-508.
24. Weiner GR, Geenen JE, Hogan WJ, Catalano MF: Use of corticosteroids in the prevention of post-ERCP pancreatitis. Gastrointest Endosc 1995;42:579-583.
25. Dumot JA, Conwell DL, O'Connor JB, Ferguson DR, Vargo JJ, Barnes DS, Shay SS, Sterling MJ, Horth KS, Issa K, Ponsky JL, Zuccaro G: Pretreatment with methylprednisolone to prevent ERCP-induced pancreatitis: a randomized, multicenter, placebo-controlled clinical trial. Am J Gastroenterol 1998;93:61-65.
26. De Palma GD, Catanzano C: Use of corticosteroids in the prevention of post-ERCP pancreatitis: results of a controlled prospective study. Am J Gastroenterol 1999;94:982-985.
27. Budzyñska A, Marek T, Nowak A, Kaczor R, Nowakowska-Dulawa E: A prospective, randomized, placebo-controlled trial of prednisone and allopurinol in the prevention of ERCP-induced pancreatitis. Endoscopy 2001;33:766-772.
28. Manolakopoulos S, Avgerinos A, Vlachogiannakos J, Armonis A, Viazis N, Papadimitriou N, Mathou N, Stefanidis G, Rekoumis G, Vienna E, Tzourmakliotis D, Raptis SA: Octreotide versus hydrocortisone versus placebo in the prevention of post-ERCP pancreatitis: a multicenter randomized controlled trial. Gastrointest Endosc 2002;55:470-475.
29. Sherman S, Blaut U, Watkins JL, Barnett J, Freeman M, Geenen J, Ryan M, Parker H, Frakes JT, Fogel EL, Silverman WB, Dua KS, Aliperti G, Yakshe P, Uzer M, Jones W, Goff J, Earle D, Temkit M, Lehman GA: Does prophylactic administration of corticosteroid reduce the risk and severity of post-ERCP pancreatitis: a randomized, prospective, multicenter study. Gastrointest Endosc 2003;58:23-29.
30. Katsinelos P, Kountouras J, Paroutoglou GT, Geltsis A, Mimidis K, Zavos C: Intravenous N-acetylcysteine does not prevent post-ERCP pancreatitis. Gastrointest Endosc 2005;62:105-111.
31. Wollschläger S, Patzold K, Bulang T, Meissner D, Porst H: Einfluss eine prophylaktischen Selensubstitution auf die Entwicklung der ERCP-bedingten akuten Pankreatitis. Med Klin 1999;94(suppl III):81-83.
32. Lavy A, Karban A, Suissa A, Yassin K, Hermesh I, Ben-Amotz A: Natural b-carotene for the prevention of post-ERCP pancreatitis. Pancreas 2004;29:e45-e50.
33. Sherman S, Lehman GA, Geenen J, Chuttani R, Kozarek RA, Pribble J, Elliott L, Souza S: Evaluation of recombinant human platelet-activating factor acetylhydrolase (RPAF-AH) for reducing the incidence and severity of post-ERCP acute pancreatitis (AP) (abstract). Gastrointest Endosc 2000;51:AB67-67.
34. Rabenstein T, Roggenbruck S, Framke B, Martus P, Fischer B, Nusko G, Muehldorfer S, Hochberger J, Ell C, Hahn EG, Schneider T: Complications of endoscopic sphincterotomy: Can heparin prevent acute pancreatitis after ERCP? Gastrointest Endosc 2002;55:476-483.
35. Rabenstein T, Fischer B, Wiessner V, Schmidt H, Radespiel-Tröger M, Hochberger J, Mühldorfer S, Nusko G, Messmann H, Schölmerich J, Schulz H-J, Schönekäs H, Hahn EG, Schneider HT: Low-molecular-weight heparin does not prevent acute post-ERCP pancreatitis. Gastrointest Endosc 2004;59:606-613.
36. Sherman S: Allopurinol for preventing post-ERCP pancreatitis? J Watch Gastroenterol 2005;6:76.
37. Devière J, Le Moine O, Van Laethem J-L, Eisendrath P, Ghilain A, Severs N, Cohard M: Interleukin 10 reduces the incidence of pancreatitis after therapeutic endoscopic retrograde cholangiopancreatography. Gastroenterology 2001;120:498-505.
38. Dumot JA, Conwell DL, Zuccaro G Jr, Vargo JJ, Shay SS, Easley KA, Ponsky JL: A randomized, double blind study of interleukin 10 for the prevention of ERCP-induced pancreatitis. Am J Gastroenterol 2001;96:2098-2102.
39. Räty S, Sand J, Pulkkinen M, Matikainen M, Nordback I: Post-ERCP pancreatitis: reduction by routine antibiotics. J Gastrointest Surg 2001;5:339-345.
40. Sudhindran S, Bromwich E, Edwards PR: Prospective randomized double-blind placebo-controlled trial of glyceryl trinitrate in endoscopic retrograde cholangiopancreatography-induced pancreatitis. Br J Surg 2001;88:1178-1182.
41. Moretó M, Zaballa M, Casado I, Merino O, Rueda M, Ramírez K, Urcelay R, Baranda A: Transdermal glyceryl trinitrate for prevention of post-ERCP pancreatitis: a randomized double-blind trial. Gastrointest Endosc 2003;57:1-7.
42. 2 in acute pancreatitis by pharmacological agents in vitro. Scand J Clin Lab Invest 1997;57:401-408.
43. Lankisch PG, Koop H, Winckler K, Kunze H, Vogt W: Indomethacin treatment of acute experimental pancreatitis in the rat. Scand J Gastroenterol 1978;13:629-633.
44. Coelle EF, Adham N, Elashoff J, Lewin K, Taylor IL: Effects of prostaglandin and indomethacin on diet-induced acute pancreatitis in mice. Gastroenterology 1983;85:1307-1312.
45. Ebbehøj N, Friis J, Svendsen LB, Bülow S, Madsen P: Indomethacin treatment of acute pancreatitis: a controlled double-blind trial. Scand J Gastroenterol 1985;20:798-800.
46. Murray B, Carter R, Imrie C, Evans S, O'Suilleabhain C: Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography. Gastroenterology 2003;124:1786-1791.
47. Cavallini G, Tittobello A, Frulloni L, Masci E, Mariani A, Di Francesco V, Gabexate in Digestive Endoscopy-Italian Group: Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. N Engl J Med 1996;335:919-923.
48. Masci E, Cavallini G, Mariani A, Frulloni L, Testoni PA, Curioni S, Tittobello A, Uomo G, Costamagna G, Zambelli S, Macarri G, Innocenti P, Dragonetti C, the Gabexate in Digestive Endoscopy - Italian Group II: Comparison of two dosing regimens of gabexate in the prophylaxis of post-ERCP pancreatitis. Am J Gastroenterol 2003;98:2182-2186.
49. Andriulli A, Clemente R, Solmi L, Terrazzi V, Surlani R, Sigillito A, Leandro G, Leo P, De Maio G, Perri F, on behalf of the Italian Group for Prevention of Acute Pancreatitis (GIPPA Study): Gabexate or somatostatin administration before ERCP in patients at high risk for post ERCP pancreatitis: a multicenter, placebo-controlled, randomized clinical trial. Gastrointest Endosc 2002;56:488-495.
50. Andriulli A, Solmi L, Loperfido S, Leo P, Festa V, Belmonte A, Spirito F, Silla M, Forte G, Terruzzi V, Marenco G, Ciliberto E, Sabatino A, Monica F, Magnolia MR, Perri F, on behalf of the Italian Group for Prevention of Acute Pancreatitis (GIPPA Study 2): Prophylaxis of ERCP-related pancreatitis: a randomized, controlled trial of somatostatin and gabexate mesylate. Clin Gastroenterol Hepatol 2004;2:713-718.
51. Saari A, Kivilaakso E, Schröder T: The influence of somatostatin on pancreatic irritation after pancreatography: an experimental and clinical study. Surg Res Commun 1988;2:271-278.
52. Persson B, Slezak P, Efendic S, Haggmark A: Can somatostatin prevent injection pancreatitis after ERCP? Hepatogastroenterology 1992;39:259-261.
53. Arcidiacono R, Gambitta P, Rossi A, Grosso C, Bini M, Zanasi G: The use of a long-acting somatostatin analogue (octreotide) for prophylaxis of acute pancreatitis after endoscopic sphincterotomy. Endoscopy 1994;26:715-718.
54. Tulassay Z, Döbrönte Z, Prónai L, Zágoni T, Juhász L: Octreotide in the prevention of pancreatic injury associated with endoscopic cholangiopancreatography. Aliment Pharmacol Ther 1998;12:1109-1112.
55. Testoni PA, Bagnolo F, Andriulli A, Bemasconi G, Crotta S, Lella F, Lomazzi A, Minoli G, Natale C, Prada A, Toti GL, Zambelli A: Octreotide 24-hour prophylaxis in patients at high risk for post-ERCP pancreatitis: results of a multicenter, randomized, controlled trial. Aliment Pharmacol Ther 2001;15:965-972.
56. Sternlieb JM, Aronchick CA, Retig JN, Dabezies M, Saunders F, Goosenberg E, Infantolino A, Ionna S, Maislin G, Wright SH, Lipschutz H: A multicenter, randomized, controlled trial to evaluate the effect of prophylactic octreotide on ERCP-induced pancreatitis. Am J Gastroenterol 1992;87:1561-1566.
57. Bordas JM, Toledo V, Mondelo F, Rodés J: Prevention of pancreatic reactions by bolus somatostatin administration in patients undergoing endoscopic retrograde cholangio-pancreatography and endoscopic sphincterotomy. Hormone Res 1988;29:106-108.
58. Poon RTP, Yeung C, Lo C-M, Yuen W-K, Liu C-L, Fan S-T: Prophylactic effect of somatostatin on post-ERCP pancreatitis: a randomized controlled trial. Gastrointest Endosc 1999;49:593-598.
59. Arvanitidis D, Anagnostopoulos GK, Giannopoulos D, Pantes A, Agaritsi R, Margantinis G, Tsiakos S, Sakorafas G, Kostopoulos P: Can somatostatin prevent post-ERCP pancreatitis? Results of a randomized controlled trial. J Gastroenterol Hepatol 2004;19:278-282.
60. Andriulli A, Leandro G, Niro G, Mangia A, Festa V, Gambassi G, Villani MR, Facciorusso D, Conoscitore P, Spirito F, De Maio G: Pharmacologic treatment can prevent pancreatic injury after ERCP: a meta-analysis. Gastrointest Endosc 2000;51:1-7.
61. Binmoeller KF, Dumas R, Harris AG, Delmont JP: Effect of somatostatin analog octreotide on human sphincter of Oddi. Dig Dis Sci 1992;37:773-777.
62. Kunze H, Nahas N, Traynor JR, Wurl M: Effects of local anaesthetics on phospholipases. Biochim Biophys Acta 1976;441:93-102.
63. Aho HJ, Nevalainen TJ, Lindberg RLP, Aho AJ: Experimental pancreatitis in the rat. The role of phospholipase A in sodium taurocholated induced acutehaemorrhagic pancreatitis. Scand J Gastroenterol 1980;15:1027-1031.
64. Jakobs R, Adamek MU, von Bubnoff AC, Riemann JF: Buprenorphine or procaine for pain relief in acute pancreatitis: a prospective randomized study. Scand J Gastroenterol 2000;35:1319-1323.
65. Kahl S, Zimmermann S, Pross M, Schulz H-U, Schmidt U, Malfertheiner P: Procaine hydrochloride fails to relieve pain in patients with acute pancreatitis. Digestion 2004;69:5-9.
66. Lerch MM: No more intravenous procaine for pancreatitis pain? Digestion 2004;69:2-4.
67. Hallberg D, Theve NO: Observations during treatment of acute pancreatitis with insulin and glucose infusion. Acta Chir Scand 1974;140:138-142.
68. Svensson J-O: Role of intravenously infused insulin in treatment of acute pancreatitis: a double-blind study. Scand J Gastroenterol 1975;10:487-490.
69. Berk JE, Krumperman LRW: The use of fractional epidural block in the management of acute pancreatitis. Am J Med Sci 1952;224:507-513.
70. Durrani Z, Winnie AP, Ikuta P: Interpleural catheter analgesia for pancreatic pain. Anesth Analg 1988;67:479-481.
71. Niesel HC, Klimpel L, Kaiser H, Bernhardt A, Al-Rafai S, Lang U: Epidurale Blockade zur Analgesie und Behandlung der akuten Pankreatitis. Reg Anaesth 1991;14:97-100.
72. Rykowski JJ, Hilgier M: Continuous celiac plexus block in acute pancreatitis. Reg Anaesth 1995;20:528-532.
73. Bernhardt A, Kortgen A, Niesel HC, Goertz A: Anwendung der Epiduralanästhesie bei Patienten mit akuter Pankreatitis - Prospektive Untersuchung an 121 Patienten. Anaesthesiol Reanimat 2002;27:16-22.
74. Stevens M, Esler R, Asher G: Transdermal fentanyl for the management of acute pancreatitis pain. Appl Nurs Res 2002;15:102-110.
75. Patankar RV, Chand R, Johnson CD: Pancreatic enzyme supplementation in acute pancreatitis. HPB Surg 1995;8:159-162.
76. Cameron JL, Mehigan D, Zuidema GD: Evaluation of atropine in acute pancreatitis. Surg Gynecol Obstet 1979;148:206-208.
77. MRC Multicentre Trial of Glucagon and Aprotinin: Death from acute pancreatitis. Lancet 1977;ii:632-635.
78. Dürr HK, Maroske D, Zelder O, Bode JC: Glucagon therapy in acute pancreatitis: report of a double-blind trial. Gut 1978;19:175-179.
79. Gauthier A, Gillet M, Di Costanzo J, Camelot G, Maurin P, Sarles H: Étude contrôlée multicentrique de l'aprotinine et du glucagon dans le traitement des pancréatites aiguës. Gastroenterol Clin Biol 1978;2:777-784.
80. Olazabal A, Fuller R: Failure of glucagon in the treatment of alcoholic pancreatitis. Gastroenterology 1978;74:489-491.
81. Kronborg O, Bülow S, Joergensen PM, Svendsen LB: A randomized double-blind trial of glucagon in treatment of first attack of severe acute pancreatitis without associated biliary disease. Am J Gastroenterol 1980;73:423-425.
82. Medical Research Council Multicentre Trial: Morbidity of acute pancreatitis: the effect of aprotinin and glucagon. Gut 1980;21:334-339.
83. Goebell H, Ammann R, Herfarth C, Horn J, Hotz J, Knoblauch M, Schmid M, Jaeger M, Akovbiantz A, Linder E, Abt K, Nüesch E, Barth E (The Pancreatitis Study Group): A double-blind trial of synthetic salmon calcitonin in the treatment of acute pancreatitis. Scand J Gastroenterol 1979;14:881-889.
84. Paul F, Ohnhaus EE, Hesch RD, Chemnitz G, Hoppe-Seyler R, Henrichs HR, Hartung H, Waldmann D, Kunze K, Barth E, Nüesch E, Abt K: Einfluss von Salm-Calcitonin auf den Verlauf der akuten Pankreatitis. Ergebnisse einer prospektiven Doppelblindstudie. Dtsch Med Wochenschr 1979;104:615-622.
85. Martinez E, Navarrete F: A controlled trial of synthetic salmon calcitonin in the treatment of severe acute pancreatitis. World J Surg 1984;8:354-359.
86. Usadel KH, Überla KK, Leuschner U: Treatment of acute pancreatitis with somatostatin: results of the multicenter double-blind trial (APTS-study) (abstract). Dig Dis Sci 1985;30:992.
87. Gjørup I, Roikjær O, Andersen B, Burcharth F, Hovendal C, Pedersen SA, Christiansen P, Wara P, Andersen JC, Balslev I, Jepsen J, Rokkjær M: A double-blinded multicenter trial of somatostatin in the treatment of acute pancreatitis. Surg Gynecol Obstet 1992;175:397-400.
88. McKay C, Baxter J, Imrie C: A randomized, controlled trial of octreotide in the management of patients with acute pancreatitis. Int J Pancreatol 1997;21:13-19.
89. Uhl W, Büchler MW, Malfertheiner P, Beger HG, Adler G, Gaus W, The German Pancreatitis Study Group: A randomised, double blind, multicentre trial of octreotide in moderate to severe acute pancreatitis. Gut 1999;45:97-104.
90. Niederau C, Niederau M, Lüthen R, Strohmeyer G, Ferrell LD, Grendell JH: Pancreatic exocrine secretion in acute experimental pancreatitis. Gastroenterology 1990;99:1120-1127.
91. Evander A, Lundquist I, Ihse I: Influence of gastrointestinal hormones on the course of acute experimental pancreatitis. Hepatogastroenterology 1982;29:161-166.
92. Lankisch PG, Göke B, Fölsch UR, Winckler K, Otto J, Creutzfeldt W: Influence of secretin on the course of acute experimental pancreatitis in rats. Digestion 1983;26:187-183.
93. Andriulli A, Leandro G, Clemente R, Festa V, Caruso N, Annese V, Lezzi G, Lichino E, Bruno F, Perri F: Meta-analysis of somatostatin, octreotide and gabexate mesilate in the therapy of acute pancreatitis. Aliment Pharmacol Ther 1998;12:237-245.
94. Trapnell JE, Rigby CC, Talbot CH, Duncan EHL: A controlled trial of Trasylol in the treatment of acute pancreatitis. Br J Surg 1974;61:177-182.
95. Imrie CW, Benjamin IS, Ferguson JC, McKay AJ, Mackenzie I, O'Neill J, Blumgart LH: A single-centre double-blind trial of Trasylol therapy in primary acute pancreatitis. Br J Surg 1978;65:337-341.
96. Yang C-Y, Chang-Chien C-S, Liaw Y-F: Controlled trial of protease inhibitor gabexelate mesilate (FOY) in the treatment of acute pancreatitis. Pancreas 1987;2:698-700.
97. Goebell H: Multicenter double-blind study of gabexate mesilate (Foy), given intravenously in low dose in acute pancreatitis (abstr). Digestion 1988;40:83-83.
98. Büchler M, Malfertheiner P, Uhl W, Schölmerich J, Stöckmann F, Adler G, Gaus W, Rolle K, Beger HG, German Pancreatitis Study Group: Gabexate mesilate in human acute pancreatitis. Gastroenterology 1993;104:1165-1170.
99. Messori A, Rampazzo R, Scroccaro G, Olivato R, Bassi C, Falconi M, Pederzoli P, Martini N: Effectiveness of gabexate mesilate in acute pancreatitis: a meta-analysis. Dig Dis Sci 1995;40:734-738.
100. Konttinen YP: Epsilon-aminocaproic acid in treatment of acute pancreatitis. Scand J Gastroenterol 1971;6:715-718.
101. Cuschieri A, Wood RAB, Cumming JRG, Meehan SE, Mackie CR: Treatment of acute pancreatitis with fresh frozen plasma. Br J Surg 1983;70:710-712.
102. Leese T, Holliday M, Heath D, Hall AW, Bell PRF: Multicentre clinical trial of low volume fresh frozen plasma therapy in acute pancreatitis. Br J Surg 1987;74:907-911.
103. Leese T, Thomas WM, Holliday M, Attard A, Watkins M, Neoptolemos JP, Hall C: A multicentre controlled clinical trial of high-volume fresh frozen plasma therapy in prognostically severe acute pancreatitis. Ann R Coll Surg Engl 1991;73:207-214.
104. Rinderknecht H: Fatal pancreatitis, a consequence of excessive leukocyte stimulation? Int J Pancreatol 1998;3:105-112.
105. Gross V, Leser H-G, Heinisch A, Schölmerich J: Inflammatory mediators and cytokines - new aspects of the pathophysiology and assessment of severity of acute pancreatitis? Hepatogastroenterology 1993;40:522-530.
106. Formela LJ, Galloway SW, Kingsnorth AN: Inflammatory mediators in acute pancreatitis. Br J Surg 1995;82:6-13.
107. Johnson CD, Kingsnorth AN, Imrie CW, McMahon MJ, Neoptolemos JP, McKay C, Toh SKC, Skaife P, Leeder PC, Wilson P, Larvin M, Curtis LD, UK Acute Pancreatitis Study Group: Double blind, randomised, placebo controlled study of a platelet activating factor antagonist, lexipafant, in the treatment and prevention of organ failure in predicted severe acute pancreatitis. Gut 2001;48:62-69.
108. Emanuelli G, Montrucchio G, Gaia E, Dughera L, Corvetti G, Gubetta L: Experimental acute pancreatitis induced by platelet activating factor rabbits. Am J Pathol 1989;134:315-326.
109. Konturek SJ, Dembinski A, Konturek PJ, Warzecha Z, Jaworek kJ, Gustaw P, Tomaszewska R, Stachura J: Role of platelet activating factor in pathogenesis of acute pancreatitis in rats. Gut 1992;33:1268-1274.
110. Formela LJ, Wood M, Whittaker M, Kingsnorth AN: Amelioration of experimental acute pancreatitis with a potent platelet-activating factor for antagonists. Br J Surg 1994;81:1783-1785.
111. Leonhardt U, Fayyazzi A, Seidensticker F, Stöckmann F, Söling H-D, Creutzfeldt W: Influence of a platelet-activating factor antagonist on severe pancreatitis in two experimental models. Int J Pancreatol 1992;12:161-166.
112. Kingsnorth AN, Galloway SW, Formela LJ: Randomized, double-blind phase II trial of Lexipafant, a platelet-activating factor antagonist, in human acute pancreatitis. Br J Surg 1995;82:1414-1420.
113. McKay CJ, Curran F, Sharples C, Baxter JN, Imrie CW: Prospective placebo-controlled randomized trial of lexipafant in predicted severe acute pancreatitis. Br J Surg 1997;84:1239-1243.
114. Rau B, Poch B, Gansauge F, Bauer A, Nüssler AK, Nevalainen T, Schoenberg MH, Beger HG: Pathophysiologic role of oxygen free radicals in acute pancreatitis. Initiating event or mediator of tissue damage? Ann Surg 2000;231:352-360.
115. 3)-Therapie. Diskussion zur gleichnamigen Arbeit von Kuklinkski B, Buchner M, Schweder R, Nagel R: in Z Gesamte Innere Med 1991;46:145-149.
116. Z Gesamte Inn Med 1992;47:163-164.
117. Virlos IT, Mason J, Schofield D, McCloy RF, Eddleston JM, Siriwardena AK: Intravenous n-acetylcysteine, ascorbic acid and selenium-based anti-oxidant therapy in severe acute pancreatitis. Scand J Gastroenterol 2003;38:1262-1267.
118. Lindner D, Lindner J, Baumann G, Dawczynski H, Bauch K: Untersuchung zur anti-oxidativen Therapie mit Natriumselenit bei akuter Pankreatitis. Ein prospektive, randomisierte Blindstudie. Medsche Klin 2004;99:708-712.
119. Beger HG, Bittner R, Block S, Büchler M: Bacterial contamination of pancreatic necrosis: a prospective clinical study. Gastroenterology 1986;91:433-438.
120. Gerzof SG, Banks PA, Robbins AH, Johnson WC, Spechler SJ, Wetzner SM, Snider JM, Langevin RE, Jay ME: Early diagnosis of pancreatic infection by computed tomography-guided aspiration. Gastroenterology 1987;93:1315-1320.
121. Fedorak IJ, Ko TC, Djuricin G, McMahon M, Thompson K, Prinz RA: Secondary pancreatic infections: are they distinct clinical entities? Surgery 1992;112:824-831.
122. Bradley EL III: A fifteen year experience with open drainage for infected pancreatic necrosis. Surg Gynecol Obstet 1993;177:215-222.
123. Banks PA, Gerzof SG, Langevin RE, Silverman SG, Sica GT, Hughes MD: CT-guided aspiration of suspected pancreatic infection: bacteriology and clinical outcome. Int J Pancreatol 1995;18:265-270.
124. Ratschko M, Fenner T, Lankisch PG: The role of antibiotic prophylaxis in the treatment of acute pancreatitis. Gastroenterol Clin N Am 1999;28:641-659.
125. Schmid SW, Uhl W, Friess H, Malfertheiner P, Büchler MW: The role of infection in acute pancreatitis. Gut 1999;45:311-316.
126. Craig RM, Dordal E, Myles L: The use of ampicillin in acute pancreatitis. Ann Intern Med 1975;83:831-832.
127. Howes R, Zuidema GD, Cameron JL: Evaluation of prophylactic antibiotics in acute pancreatitis. J Surg Res 1975;18:197-200.
128. Finch WT, Sawyers JL, Schenker S: A prospective study to determine the efficacy of antibiotics in acute pancreatitis. Ann Surg 1976;183:667-671.
129. Roberts EA, Williams RJ: Ampicillin concentrations in pancreatic fluid bile obtained at endoscopic retrograde cholangiopancreatography (ERCP). Scand J Gastroenterol 1979;14:669-672.
130. Büchler M, Malfertheiner P, Friess H, Isenmann R, Vanek E, Grimm H, Schlegel P, Friess T, Beger HG: Human pancreatic tissue concentration of bactericidal antibiotics. Gastroenterology 1992;103:1902-1908.
131. Bassi C, Pederzoli P, Vesentini S, Falconi M, Bonora A, Abbas H, Benini A, Bertazzoni EM: Behavior of antibiotics during human necrotizing pancreatitis. Antimicrobial Agents Chemother 1994;38:830-836.
132. Pederzoli P, Bassi C, Vesentini S, Campedelli A: A randomized multicenter clinical trial of antibiotic prophylaxis of septic complications in acute necrotizing pancreatitis with imipenem. Surg Gynecol Obstet 1993;176:480-483.
133. Sainio V, Kemppainen E, Puolakkainen P, Taavitsainen M, Kivisaari L, Valtonen V, Haapiainen R, Schröder T, Kivilaakso E: Early antibiotic treatment in acute necrotising pancreatitis. Lancet 1995;346:663-667.
134. Delcenserie R, Yzet T, Ducroix JP: Prophylactic antibiotics in treatment of severe acute alcoholic pancreatitis. Pancreas 1996;13:198-201.
135. Schwarz M, Isenmann R, Meyer H, Beger HG: Antibiotika bei nekrotisierender Pankreatitis. Ergebnisse einer kontrollierten Studie. Dtsch Med Wochenschr 1997;122:356-361.
136. Golub R, Siddiqi F, Pohl D: Role of antibiotics in acute pancreatitis: a meta-analysis. J Gastrointest Surg 1998;2:496-503.
137. Sharma VK, Howden CW: Prophylactic antibiotic administration reduces sepsis and mortality in acute necrotizing pancreatitis: a meta-analysis. Pancreas 2001;22:28-31.
138. Bradley EL III: A clinically based classification system for acute pancreatitis. Summary of the International Symposium on Acute Pancreatitis, Atlanta, Ga., September 11 through 13, 1992. Arch Surg 1993;128:586-590.
139. Glazer G, Mann DV: United Kingdom guidelines for the management of acute pancreatitis. Gut 1998;42(suppl 2):S1-S13.
140. SSAT: SSAT patient care guidelines: treatment of acute pancreatitis. J Gastrointest Surg 1998;2:487-488.
141. Dervenis C, Johnson CD, Bassi C, Bradley E, Imrie CW, McMahon MJ, Modlin I: Diagnosis, objective assessment of severity, and management of acute pancreatitis. Int J Pancreatol 1999;25:195-210.
142. Rünzi M, Layer P, Büchler MW, Beger HG, Ell C, Fölsch UR, Goebell H, Hopt UT, Lankisch PG, Schmidt WE, Schmiegel W, Schölmerich J: Therapie der akuten Pankreatitis. Gemeinsame Leitlinien. Z Gastroenterol 2000;38:571-581.
143. Mayumi T, Ura H, Arata S, Kitamura N, Kiriyama I, Shibuya K, Sekimoto M, Nago N, Hirota M, Yoshida M, Ito Y, Hirata K, Takada T: evidence-based clinical practice guidelines for acute pancreatitis: proposals. J Hepatobiliary Pancreat Surg 2002;9:413-422.
144. Toouli J, Brooke-Smith M, Bassi C, Carr-Locke D, Telford J, Freeney P, Imrie C, Tandon R: Working party report: guidelines for the management of acute pancreatitis. J Gastroenterol Hepatol 2002;17(suppl):S15-S39.
145. Uhl W, Warshaw A, Imrie C, Bassi C, McKay C, Lankisch PG, Carter R, DiMagno E, Banks PA, Whitcomb DC, Dervenis C, Ulrich CD, Satake K, Ghaneh P, Hartwig W, Werner J, McEntee G, Neoptolemos JP, Büchler MW: IAP guidelines for the surgical management of acute pancreatitis. Pancreatology 2002;2:565-573.
146. Brown A: Prophylactic antibiotic use in severe acute pancreatitis: hemlock, help, or hype? Gastroenterology 2004;126:1195-1198.
147. Mithöfer K, Fernández-del Castillo C, Ferraro MJ, Lewandrowski K, Rattner DW, Warshaw AL: Antibiotic treatment improves survival in experimental acute necrotizing pancreatitis. Gastroenterology 1996;110:232-240.
148. Isenmann R, Rünzi M, Kron M, Kahl S, Kraus D, Jung N, Maier L, Malfertheiner P, Goebell H, Beger HG, The German Antibiotics in Severe Acute Pancreatitis (ASAP) Study Group: Prophylactic antibiotic treatment in patients with predicted severe acute pancreatitis: a placebo-controlled, double-blind trial. Gastroenterology 2004;126:997-1004.
149. Manes G, Rabitti PG, Menchise A, Riccio E, Balzano A, Uomo G: Prophylaxis with meropenem of septic complications in acute pancreatitis: a randomized, controlled trial versus imipenem. Pancreas 2003;17:e79-e83.
150. Bassi C, Falconi M, Talamini G, Uomo G, Papaccio G, Dervenis C, Salvia R, Bertazzoni Minelli E, Pederzoli P: controlled clinical trial of pefloxacin versus imipenem in severe acute pancreatitis. Gastroenterology 1998;115:1513-1517.
151. Howard TJ, Temple MB: prophylactic antibiotics alter the bacteriology of infected necrosis in severe acute pancreatitis. J Am Coll Surg 2002;195:759-767.
152. Gloor B, Schmidt O, Uhl W, Büchler MW: Acute pancreatitis: threat of fungal infection. Pancreatology 2001;1:213-216.
153. De Waele JJ, Vogelaers D, Blot S, Colardyn F: fungal infections in patients with severe acute pancreatitis and the use of prophylactic therapy. Clin Infect Dis 2003;37:208-213.
154. Gloor B, Müller CA, Worni M, Stahel PF, Redaelli C, Uhl W, Büchler MW: Pancreatic infection in severe pancreatitis: the role of fungus and multiresistant organisms. Arch Surg 2001;136:592-596.
155. Nordback I, Sand J, Saaristo J, Saaristo R, Paajanen H: Early treatment with antibiotics reduces the need for surgery in acute necrotizing pancreatitis: a single-center randomized study. J Gastrointest Surg 2001;5:113-120.
156. Katsinelos P, Kountouras J, Chatzis J, Christodoulou K, Paroutoglou G, Mimidis K, Beltsis A, Zavos C: High-dose allopurinol for prevention of post-ERCP pancreatitis: a prospective randomized double-blind controlled trial. Gastrointest Endosc 2005;61:407-415.
157. Mosler P, Sherman S, Marks J, Watkins JL, Geenen JE, Jamidar P, Fogel EL, Lazzell-Pannell L, Temkit M, Tarnasky P, Block KP, Frakes JT, Aziz AA, Malik P, Nickl N, Slivka A, Goff J, Lehman GA: Oral allopurinol does not prevent the frequency or the severity of post-ERCP pancreatitis. Gastrointest Endosc 2005;62:245-250.
158. Harewood GC, Topazian M: Post-ERCP pancreatitis: is allopurinol the holy grail? Gastrointest Endosc 2005;62:251-252.